Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
As of September 30, 2019 we had cash of $7,885 and as of September 30, 2020 we had cash of 0. The reduction in cash is primarily attributable to funds expended in the operation of the Company’s business.
As of September 30, 2019 we had Accounts Receivable, Related Party of $71,186 and as of September 30, 2020 we had Accounts Receivable, Related Party of $ 103,192.
The increase in Accounts Receivable, Related Party of approximately 44.9% is primarily attributable to:
(a) The recognition by the Company during the quarter ended December 31, 2019 of an aggregate of $27,424 of minimum royalties and anniversary fees pursuant to a license granted to Zander by Regen Biopharma, Inc.
(b) The recognition by the Company during the quarter ended March 31, 2020 of an aggregate of $27,425 of minimum royalties and anniversary fees pursuant to a license granted to Zander by Regen Biopharma, Inc.
(c) The recognition by the Company during the quarter ended June 30, 2020 of an aggregate of $27,425 of minimum royalties and anniversary fees pursuant to a license granted to Zander by Regen Biopharma, Inc.
(d) The recognition by the Company during the quarter ended September 30, 2020 of an aggregate of $27,726 of minimum royalties and anniversary fees pursuant to a license granted to Zander by Regen Biopharma, Inc.
Offset by:
The application of $75,900 of principal indebtedness and $2,093 of interest accrued but unpaid owed to Zander by the Company toward Accounts Receivable during the quarter ended December 31, 2019.
On December 16, 2019 Zander Therapeutics, Inc. (“Zander”), KCL Therapeutics, Inc. (“KCL”) and Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) whereby:
1) Zander shall return for cancellation 194,285,714 shares of the Series A Preferred stock of Regen (“Conversion Shares”) acquired by Zander through conversion of $340,000 of principal indebtedness of a $350,000 convertible note payable issued by Regen to Zander. Subsequent to this event the principal amount due to Zander by Regen pursuant to the Convertible Note shall be $350,000 which shall be applied pursuant to the Agreement.
2) A $35,000 one-time charge due to Zander by Regen (“One Time Charge”) shall be applied pursuant to the Agreement.
3) $75,900 of principal indebtedness due to Regen by Zander and $4,328 of accrued but unpaid interest due by Regen to Zander shall be applied pursuant to the Agreement.
No actions were taken by any of the parties to enforce the terms of the Agreement.
On April 15, 2021 the Agreement was amended as follows so that the material terms and conditions shall be:
a) Zander shall not return the Conversion shares for cancellation and the principal indebtedness of the aforementioned convertible note shall not reflect such return
b) As of December 16, 2019 all principal and accrued interest payable by Regen to Zander on that date resulting from Promissory Notes issued by Regen to Zander shall be credited towards amounts due by Zander pursuant to that agreement, as amended, entered into by and between Zander and Regen on June 23, 2015 (“License Agreement”) whereby Regen granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by Regen for non-human veterinary therapeutic use for a term of fifteen years and that License Assignment And Consent agreement entered into by and between Regen, KCL and Zander on December 17, 2018 whereby Regen transferred and assigned to KCL all rights, duties, and obligations of Regen under the License Agreement and KCL agreed to assume such duties and obligations thereunder and be bound to the terms of the License Agreement with respect thereto.
The Financial Statements for the fiscal year ended September 30, 2020 recognize the application as of December 16, 2019 of all principal and accrued interest payable by Regen to Zander on that date resulting from Promissory Notes issued by Regen to Zander.
As of September 30, 2019 we had Accounts Payable of $92,000 and as of September 30,2020 we had Accounts Payable of $110,486. The increase of approximately 20% is primarily attributable expenses incurred by the Company resulting from services provided to the Company by Baumgartner Patent Law and Securities Transfer Corporation.
As of September 30, 2019 we had Notes Payable of $88,627 and as of September 30, 2020 we had Notes Payable of $62,127. The decrease in Notes Payable of approximately 29.9% is attributable to $37,900 loaned to the Company by BST Partners, a company controlled by David Koos the Company’s Chairman and Chief Executive Officer, during the year ended September 30, 2020 offset by the application towards Accounts Receivable of principal amounts owed by the Company to Zander Therapeutics, Inc. as of December 16, 2019 resulting from Promissory Notes issued by Regen to Zander.
As of September 30, 2019 we had Accrued Interest Payable of $525,335 and as of September 30, 2020 we had Accrued Interest Payable of $830,061.
The increase in Accrued Interest Payable of approximately 58% is attributable to additional interest accrued but unpaid on Notes and Convertible Notes issued by the Company during the twelve months ended September 30, 2020 offset by:
(a) application of $2,093 of interest due but unpaid to Zander Therapeutics Inc. towards Accounts Receivable.
(b) conversion of $26,589 of interest accrued but unpaid due to holders of Convertible Notes Payable into equity securities of the Company.
As of September 30, 2020, we had Accrued Payroll of $1,189,319 and as of September 30, 2019 we had Accrued Payroll of $972,158.
The increase in accrued payroll of approximately 22% is attributable to:
$55,161 in salary expense due to the Company’s Chief Executive Officer incurred but unpaid during the twelve months ended September 30, 2020
$162,000 in salary expense due to the Company’s Chief Financial Officer incurred but unpaid during the twelve months ended September 30, 2020
As of September 30, 2020 we had Accrued Rent of $23,548 and as of September 30, 2019 we had Accrued Rent of $ 5,000.
The increase in Accrued Rent of approximately 370.9% is attributable to rental expenses incurred yet unpaid during the year ended September 30, 2020 pursuant to a month to month sublease agreement by and between the Company and BST Partners ( an entity under common control with the Company).
On January 20, 2020 the Company and BST Partners agreed that the month to month sublease by and between the Company and BST Partners, Inc. whereby the Company subleased office space from BST Partners, Inc.at 4700 Spring Street, St 304, La Mesa, California 91942 shall terminate as of 1pm Pacific Standard Time on January 22, 2020.
As of September 30, 2020 we had a Derivative Liability of $2,634,215 and as of September 30, 2019 we had a Derivative Liability of $7,200,528.
The decrease in Derivative Liability of 63.4% is attributable to the recognition by the Company of embedded derivatives on Convertible Notes Payable with an aggregate face value of $2,089,377 outstanding as of September 30, 2020.
As of September 30, 2019 we had Convertible Notes Payable, Net of Unamortized Discount, of $2,058,571 and as of September 30, 2020 we had Convertible Notes Payable, Net of Unamortized Discount, of $2,541,766.
The increase in Convertible Notes Payable, Net of Unamortized Discount, of approximately 23.4 % is primarily attributable to amortization of $609,522 of Discounts on Convertible Notes offset by the conversion of approximately $126,133 of principal indebtedness into equity securities of the Company.
Material Changes in Results of Operations
Revenues from continuing operations were $110,000 for the twelve months ended September 30, 2019 and $110,000 for the same period ended 2020. $110,000 of revenue recognized during the years ended September 30, 2019 and September 30,2020 consisted of $100,000 related to an anniversary expense receivable pursuant to a license granted by the Company to Zander Therapeutics, Inc. and $10,000 of minimum royalties recognized during the twelve months ended September 30 2019 and 2020 respectively pursuant to the same license.
With regards to the aforementioned license, On December 17, 2018 Regen Biopharma, Inc.(“Licensor”) , KCL Therapeutics, Inc. (“Assignee”) and Zander Therapeutics, Inc. (“Licensee”) entered into a LICENSE ASSIGNMENT AND CONSENT AGREEMENT whereby, with regards to certain intellectual property which was assigned by Regen Biopharma, Inc.(“Assigned Properties”) to its wholly owned subsidiary KCL Therapeutics, Inc., Licensor hereby transfers and assigns to Assignee all rights, duties, and obligations of Licensor under the Agreement with respect to the Assigned Properties , and Assignee agrees to assume such duties and obligations thereunder and be bound to the terms of the Agreement with respect thereto.
Operating Loss for the twelve months ended September 30, 2019 was $756,785 as opposed to Operating Loss recognized in the same period ended 2020 of $209,317. The decrease in Operating Loss recognized in the twelve months ended 2020 as opposed to the twelve months ended 2019 is attributable to higher General and Administrative, Consulting, and Research and Development expenses recognized during the twelve months ended September 30, 2019 as compared to the same period ended 2020
Net Los for the year ended September 30, 2019 was $2,623,176. Net Income for the year ended September 30, 2020 was $3,414,419. The disparity is primarily attributable to Derivative Income of $4,566,669 recognized for the year ended September 30, 2020.
As of September 30, 2020 we had $0 in cash on hand and current liabilities of $7,458,187 such liabilities consisting of Accounts Payable, Notes Payable, Convertible Notes Payable ( Net of Unamortized Discount), Derivative Liability Recognized, Accrued Rent and Accrued Expenses. We feel we will not be able to satisfy our cash requirements over the next twelve months and shall be required to seek additional financing.
As of September 30, 2019 the Company was not party to any binding agreements which would commit Regen to any material capital expenditures.